Home Contact Sitemap

WILEX AG

Company

Portfolio

Partner

Technologies

Press + Investors

Career

- Strategy
- Facts
- Share
- Announcements
- Financial reports
- Presentations
- Annual General Meeting
- Corporate Governance
- Financial Calendar
- Conferences
- Annual Document
  - 2011
  - 2010
  - 2009
  - 2008
  - 2007
  - 2006
- IR Service
- IR/PR Contact
- Pressphotos

Contact
Katja Arnold (CIRO)
Corporate Communications
Tel.: +49-89-41 31 38-126
Email: investors[at]wilex.com

Download
Annual Report 2011
3-Month Financial Report 2012

Annual Document

Print This Page

Print This Page |

Email This Page

Email This Page

Seite gelesen: 417 | Heute: 4

Overview
WILEX subsidiaries
Management Team
Supervisory Board
Medical Advisory Board
History
Contact
Facility

Pipeline
Philosophy
RENCAREX®
REDECTANE®
MESUPRON®
WX-554
WX-037
Research Projects
Publications
For Patients

Cooperations
Commercialisation

TECHNOLOGIES

Antibodies
Small molecules
ADC-Technology
Diagnostics

PRESS + INVESTORS

Strategy
Facts
Share
Announcements
Financial reports
Presentations
Annual General Meeting
Corporate Governance
Financial Calendar
Conferences
Annual Document
IR Service
IR/PR Contact
Pressphotos

WILEX AG - Focused Cancer Therapies | Grillparzerstr. 10, 81675 Munich | Germany | Tel. +49 (0)89 41 31 38 - 0 | Fax +49 (0)89 41 31 38 - 99

Imprint | Disclaimer | Privacy Policy © WILEX AG | RENCAREX®, REDECTANE® and MESUPRON® are registered trademarks.